• Axsome Therapeutics presented new Phase 3 data on AXS-12 in narcolepsy at a major sleep medicine conference.
• The company also shared Phase 3 and post hoc analyses on solriamfetol related to sleep disorders such as sleep apnea.
• These presentations focus on central nervous system conditions and add fresh clinical detail to Axsome Therapeutics' late stage pipeline.

Axsome Therapeutics (NasdaqGM:AXSM) is drawing attention after releasing new Phase 3 and post hoc data on AXS-12 and solriamfetol at a leading sleep medicine meeting. The stock recently traded at $253.4, with returns of 7.8% over the past week and 41.8% year to date. Over the past year, NasdaqGM:AXSM is up 149.2%, and 258.2% over five years.

For investors following Axsome Therapeutics, the latest conference presentations add fresh context to a central nervous system focused pipeline that already carries high expectations. The reception of these data by clinicians and regulators, along with any future regulatory milestones, may be an important reference point for how the company positions AXS-12 and solriamfetol in markets such as narcolepsy and sleep apnea.

Stay updated on the most important news stories for Axsome Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Axsome Therapeutics.

Quick Assessment

• ✅ Price vs Analyst Target: Axsome Therapeutics trades at $253.40 versus a consensus target of $275.28, around 8% below where analysts currently sit.
• ✅ Simply Wall St Valuation: The stock is flagged as undervalued, trading about 68.1% below one estimate of fair value.
• ✅ Recent Momentum: The 30 day return of 11.3% shows positive short term momentum into the new Phase 3 data.

There's only one way to know the right time to buy, sell or hold Axsome Therapeutics. Head to Simply Wall St's company report for the latest analysis of Axsome Therapeutics's Fair Value.

Key Considerations

• 📊 The new Phase 3 results for AXS-12 and solriamfetol feed directly into how investors view Axsome Therapeutics' central nervous system portfolio and potential future revenue mix.
• 📊 Watch how the share price trades relative to the $275.28 analyst target and any updates to fair value estimates as more detail on efficacy and safety is absorbed.
• ⚠️ With no flagged company specific risks in the dataset, the key risk is still clinical and regulatory uncertainty around how these Phase 3 findings translate into approvals and real world adoption.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Axsome Therapeutics analysis. Alternatively, you can check out the community page for Axsome Therapeutics to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.